Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003119452 | SCV003793023 | pathogenic | Hereditary spastic paraplegia 4 | 2022-09-10 | criteria provided, single submitter | clinical testing | This variant disrupts a region of the SPAST protein in which other variant(s) (p.Arg562Gln) have been determined to be pathogenic (PMID: 11843700, 17971434, 19423133, 25326637, 27334366). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with SPAST-related conditions. This variant results in the deletion of part of exon 15 (c.1643_1688-530del) of the SPAST gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SPAST are known to be pathogenic (PMID: 20932283). |